Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

A triple-board-certified MD of lifestyle and obesity medicine lists the foods that will optimize your medication's efficacy ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.

About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration ...

Allurion's new program uses artificial intelligence guidance to help patients adhere to a well-rounded diet and exercise ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...